Company intelligence / Profile preview

CellViderm

Ownership: Private
Development stage: Other

Overview

CellViderm is an emerging biotechnology company focused on developing advanced regenerative therapies for dermatological conditions and complex wound healing. The company utilizes its proprietary CellVi-Regen platform to engineer cell-based treatments and small molecule modulators that accelerate tissue repair and restore skin integrity. CellViderm's primary research efforts are directed toward chronic wounds, such as diabetic foot ulcers, and severe skin injuries. By integrating cell biology with innovative delivery systems, the company aims to provide transformative solutions for patients with limited treatment options in the wound care space.

Therapeutic areas: Dermatology
Modalities: Cell therapySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on CellViderm.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CellViderm.

Explore the full profile